Unusual Cutaneous Reaction at Site of Methotrexate Injection in Two Patients with Psoriasis and Psoriatic Arthritis
DOI:
https://doi.org/10.2340/actadv.v101.352Keywords:
psoriasis, injection site reaction, methotrexate, side effect, adverse reactionAbstract
Abstract is missing (Short communication)
Downloads
References
Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983-994.
https://doi.org/10.1016/S0140-6736(14)61909-7 DOI: https://doi.org/10.1016/S0140-6736(14)61909-7
Nast A, Boehncke WH, Morwitz U, Ockenfels HM, Philipp S, Rosenbach T, et al. S3 guidelines for the treatment of psoriasis vulgaris. Update 2011. Available from: http://www.awmf.org/uploads/tx_szleitlinien/013-001l_S3_Psoriasis_vulgaris_Therapie_01.pdf.
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2021; 4: CD011535.
https://doi.org/10.1002/14651858.CD011535.pub4 DOI: https://doi.org/10.1002/14651858.CD011535.pub4
Shiver MB, Hall AE, Conner KB, Brown GE, Cheung WL, Wirges ML. Cutaneous erosions: a herald for impending pancytopenia in methotrexate toxicity. Dermatol Online J 2014; 20: 13030.
https://doi.org/10.5070/D3207023133 DOI: https://doi.org/10.5070/D3207023133
Czarnecka-Operacz M, Sadowska-Przytocka A. The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatol Allergol 2014; 31: 392-400.
https://doi.org/10.5114/pdia.2014.47121 DOI: https://doi.org/10.5114/pdia.2014.47121
Delyon J, Ortonne N, Benayoun E, Moroch J, Wolkenstein P, Sbidian E, et al. O. Low-dose methotrexate induced skin toxicity: keratinocyte dystrophy as a histologic marker. J Am Acad Dermatol 2015; 73: 484-490.
https://doi.org/10.1016/j.jaad.2015.06.015 DOI: https://doi.org/10.1016/j.jaad.2015.06.015
Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein Arch Dermatol 2001; 137: 893-899.
Shear NH, Paul C, Blauvelt A Gooderham M, Leonardi C, Reich K, et al. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. J Drugs Dermatol 2018; 17: 200-206.
Corominas M, Gastaminza G, Lobera T. Hypersensitivity reactions to biological drugs. J Invest Allergol Clin Immunol 2014; 24: 212-225.
Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF alpha blocking agents with positive skin tests. Allergy 2008; 63: 138-139.
https://doi.org/10.1111/j.1398-9995.2007.01536.x DOI: https://doi.org/10.1111/j.1398-9995.2007.01536.x
Nakamizo S, Miyachi Y, Kabashima K. Addition of cyclosporine to adalimimab improved psoriasis and adalimumab. Induced injection site reaction. Indian J Dermatol 2014; 59: 522-523.
https://doi.org/10.4103/0019-5154.139924 DOI: https://doi.org/10.4103/0019-5154.139924
Özkaya E. Fixed drug eruption: state of the art. J Dtsch Dermatol Ges 2008; 6: 181-188.
https://doi.org/10.1111/j.1610-0387.2007.06491.x DOI: https://doi.org/10.1111/j.1610-0387.2007.06491.x
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Birgit Sadoghi, Birger Kränke, Lorenzo Cerroni, Wolfgang Weger
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
